Xilio Therapeutics is a technology company.
Xilio Therapeutics has raised $225.0M across 3 funding rounds.
Xilio Therapeutics has raised $225.0M in total across 3 funding rounds.
Xilio Therapeutics has raised $225.0M in total across 3 funding rounds.
Xilio Therapeutics's investors include Abingworth, Bain Capital Life Sciences, Foresite Capital, MRL Ventures Fund, RiverVest, SV Health Investors, Giovanni Ferrara.
Xilio Therapeutics is a clinical-stage biotechnology company focused on developing novel tumor-activated immuno-oncology (I-O) therapies aimed at improving cancer treatment outcomes. Their proprietary platform engineers biologics that remain inactive systemically but become selectively activated within the tumor microenvironment (TME), thereby enhancing efficacy while reducing systemic toxicity. Xilio’s pipeline includes masked bispecific antibodies and masked T cell engagers designed to target difficult-to-treat cancers, offering hope for improved therapeutic indices and patient outcomes[1][2][3].
Founded by a team with deep expertise in oncology drug development, Xilio Therapeutics emerged to address the limitations of existing immuno-oncology therapies, particularly their systemic toxicities. The leadership includes experts like Akintunde Bello, Ph.D., with over 25 years in oncology drug development, and Daniel Curran, M.D., a pharmaceutical strategy veteran. The company’s concept originated from the need to harness tumor-specific enzymatic activity—such as matrix metalloproteases (MMPs)—to activate therapies selectively within tumors, a strategy that has driven early clinical progress and collaborations, including a notable partnership with AbbVie[1][3][4].
Xilio is positioned at the intersection of immuno-oncology and precision biologics, riding the trend toward safer, more effective cancer immunotherapies. The timing is critical as the oncology field seeks to overcome the dose-limiting toxicities of current I-O agents by improving tumor selectivity. Market forces such as increasing cancer incidence, demand for personalized therapies, and advances in tumor biology favor Xilio’s approach. By focusing on tumor-activated therapies, Xilio contributes to a paradigm shift in cancer treatment, potentially enabling broader use of immunotherapies with improved patient tolerability and outcomes[1][2].
Xilio Therapeutics is poised to advance its clinical pipeline and expand collaborations, potentially accelerating the availability of tumor-selective immunotherapies. Future trends shaping their journey include deeper understanding of the TME, advances in biologic engineering, and regulatory support for precision oncology. As their platform matures, Xilio could influence the broader immuno-oncology ecosystem by setting new standards for therapeutic index optimization and safety. Their success may unlock new treatment avenues for patients with hard-to-treat cancers, fulfilling their mission to transform cancer care[1][2][3].
Xilio Therapeutics has raised $225.0M across 3 funding rounds. Most recently, it raised $95.0M Series C in February 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2021 | $95.0M Series C | Abingworth, Bain Capital Life Sciences, Foresite Capital, MRL Ventures Fund, RiverVest, SV Health Investors, Giovanni Ferrara | |
| Feb 1, 2020 | $100.0M Series B | Abingworth, Bain Capital Life Sciences, MRL Ventures Fund, RiverVest, SV Health Investors, Giovanni Ferrara | |
| Sep 1, 2018 | $30.0M Series A | SV Health Investors, Giovanni Ferrara |